{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T15:11:26Z","timestamp":1789053086574,"version":"build-2803163510"},"reference-count":22,"publisher":"American Medical Association (AMA)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"\n Importance<\/jats:title>\n Prostate cancer care has evolved substantially during the past decade, with increasing use of systemic therapies across the disease spectrum. How these changes have affected the composition of spending for prostate cancer\u2013related health care remains incompletely characterized.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To evaluate temporal trends in prostate cancer\u2013related health care expenditures and identify the major components of care accounting for changes in spending from 2012 to 2021.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This population-level economic evaluation used Surveillance, Epidemiology, and End Results (SEER)\u2013Medicare linked data from January 1, 2012, to December 31, 2021. The analysis was performed in January 2026. Participants included fee-for-service Medicare beneficiaries with histologically confirmed prostate adenocarcinoma and prostate cancer\u2013related claims during the study period.<\/jats:p>\n <\/jats:sec>\n \n Exposures<\/jats:title>\n Calendar year and category of services for prostate cancer\u2013related health care.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n Annual aggregate prostate cancer\u2013related Medicare expenditures were inflation-adjusted to 2017 US dollars and categorized by radiotherapy, surgery, cryotherapy and\/or high-intensity focused ultrasonography, systemic therapy, and diagnostic and monitoring services. Systemic therapy expenditures were further categorized as first-generation androgen deprivation therapy, second-generation androgen receptor\u2013targeted therapy, and other systemic therapies.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n In the descriptive fee-for-service cohort at diagnosis, 1\u202f231\u202f567 beneficiaries were included; the mean (SD) age was 73.2 (7.7) years. Aggregate prostate cancer\u2013related expenditures increased from $504 million in 2012 to $1.9 billion in 2021. Radiotherapy accounted for $227 million (45.0%) in 2012 and $228 million (12.0%) in 2021, reflecting relatively stable absolute expenditures but a declining share of total spending. Surgery accounted for $53 million (10.5%) in 2012 and $67 million (3.5%) in 2021. In contrast, systemic therapy spending increased from $142 million (28.1%) in 2012 to $1.4 billion (74.0%) in 2021. By 2021, second-generation androgen receptor\u2013targeted therapy accounted for $1.2 billion (86.6% of systemic therapy spending and 64.0% of total prostate cancer\u2013related expenditures).<\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n In this economic evaluation of SEER-Medicare data, spending for prostate cancer\u2013related health care increased substantially from 2012 to 2021, with a marked shift toward systemic therapy. These findings suggest that prolonged systemic treatment has become a dominant component of prostate cancer spending and should be central to future discussions of health care sustainability.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2026.33031","type":"journal-article","created":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T15:00:35Z","timestamp":1789052435000},"page":"e2633031","source":"Crossref","is-referenced-by-count":0,"title":["Patterns of Health Care Spending in Prostate Cancer"],"prefix":"10.1001","volume":"9","author":[{"given":"Jiaye","family":"Shen","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, University of Kansas Medical Center, Kansas City"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron J.","family":"Katz","sequence":"additional","affiliation":[{"name":"Department of Population Health, University of Kansas Medical Center, Kansas City"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yahui","family":"Xie","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University of Kansas Medical Center, Kansas City"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald C.","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University of Kansas Medical Center, Kansas City"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mutlay","family":"Sayan","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Brigham and Women\u2019s Hospital and Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2026,9,10]]},"reference":[{"issue":"1","key":"zoi260903r1","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3322\/caac.21871","article-title":"Cancer statistics, 2025.","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J Clin"},{"issue":"20","key":"zoi260903r2","doi-asserted-by":"publisher","first-page":"3252","DOI":"10.1002\/cncr.34905","article-title":"The cost burden of metastatic prostate cancer in the US populations covered by employer-sponsored health insurance.","volume":"129","author":"Horn\u00fd","year":"2023","journal-title":"Cancer"},{"issue":"1","key":"zoi260903r3","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1001\/jamaoncol.2018.3701","article-title":"Total Medicare costs associated with diagnosis and treatment of prostate cancer in elderly men.","volume":"5","author":"Trogdon","year":"2019","journal-title":"JAMA Oncol"},{"issue":"11","key":"zoi260903r4","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.43449","article-title":"Low-value prostate-specific antigen test for prostate cancer screening and subsequent health care utilization and spending.","volume":"5","author":"Kim","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"18","key":"zoi260903r5","doi-asserted-by":"publisher","first-page":"3591","DOI":"10.1002\/cncr.30784","article-title":"Impact of subsequent metastases on costs and medical resource use for prostate cancer patients initially diagnosed with localized disease.","volume":"123","author":"Li","year":"2017","journal-title":"Cancer"},{"issue":"6","key":"zoi260903r6","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.35795","article-title":"Utilization, health care expenditures, and patient costs of definitive treatment modalities for localized prostate cancer in the United States.","volume":"131","author":"Sebastian","year":"2025","journal-title":"Cancer"},{"issue":"5","key":"zoi260903r7","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1016\/j.ijrobp.2026.02.204","article-title":"Changes over time in total Medicare costs for active surveillance versus radiation therapy in prostate cancer.","volume":"125","author":"Shen","year":"2026","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"21","key":"zoi260903r8","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1014618","article-title":"Abiraterone and increased survival in metastatic prostate cancer.","volume":"364","author":"de Bono","year":"2011","journal-title":"N Engl J Med"},{"issue":"2","key":"zoi260903r9","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1056\/NEJMoa1903835","article-title":"Enzalutamide with standard first-line therapy in metastatic prostate cancer.","volume":"381","author":"Davis","year":"2019","journal-title":"N Engl J Med"},{"issue":"1","key":"zoi260903r10","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1056\/NEJMoa1903307","article-title":"Apalutamide for metastatic, castration-sensitive prostate cancer.","volume":"381","author":"Chi","year":"2019","journal-title":"N Engl J Med"},{"issue":"16","key":"zoi260903r15","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1001\/jama.2025.0228","article-title":"Prostate cancer: a review.","volume":"333","author":"Raychaudhuri","year":"2025","journal-title":"JAMA"},{"issue":"11","key":"zoi260903r16","doi-asserted-by":"publisher","first-page":"469","DOI":"10.6004\/jnccn.2025.0052","article-title":"Prostate Cancer, version 3.2026, NCCN Clinical Practice Guidelines in Oncology.","volume":"23","author":"Spratt","year":"2025","journal-title":"J Natl Compr Canc Netw"},{"issue":"8","key":"zoi260903r17","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1056\/NEJMoa1503747","article-title":"Chemohormonal therapy in metastatic hormone-sensitive prostate cancer.","volume":"373","author":"Sweeney","year":"2015","journal-title":"N Engl J Med"},{"issue":"4","key":"zoi260903r18","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1056\/NEJMoa1704174","article-title":"Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer.","volume":"377","author":"Fizazi","year":"2017","journal-title":"N Engl J Med"},{"issue":"12","key":"zoi260903r19","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1056\/NEJMoa2119115","article-title":"Darolutamide and survival in metastatic, hormone-sensitive prostate cancer.","volume":"386","author":"Smith","year":"2022","journal-title":"N Engl J Med"},{"issue":"3","key":"zoi260903r20","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/j.eururo.2009.11.008","article-title":"Cost comparison of robotic, laparoscopic, and open radical prostatectomy for prostate cancer.","volume":"57","author":"Bolenz","year":"2010","journal-title":"Eur Urol"},{"issue":"18","key":"zoi260903r21","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1200\/JCO.2017.75.5371","article-title":"Comparative toxicities and cost of intensity-modulated radiotherapy, proton radiation, and stereotactic body radiotherapy among younger men with prostate cancer.","volume":"36","author":"Pan","year":"2018","journal-title":"J Clin Oncol"},{"issue":"20","key":"zoi260903r22","doi-asserted-by":"publisher","first-page":"3652","DOI":"10.1200\/JCO.23.00155","article-title":"Initial management of noncastrate advanced, recurrent, or metastatic prostate cancer: ASCO guideline update.","volume":"41","author":"Virgo","year":"2023","journal-title":"J Clin Oncol"},{"key":"zoi260903r11","unstructured":"Two studies for patients with high risk prostate cancer testing less intense treatment for patients with a low gene risk score and testing a more intense treatment for patients with a high gene risk score, The PREDICT-RT Trial. ClinicalTrials.gov identifier: NCT04513717. Updated June 25, 2026. Accessed April 7, 2026. https:\/\/clinicaltrials.gov\/study\/NCT04513717"},{"key":"zoi260903r12","unstructured":"Two studies for patients with unfavorable intermediate risk prostate cancer testing less intense treatment for patients with a low gene risk score and testing a more intense treatment for patients with a higher gene risk score, The Guidance Trial. ClinicalTrials.gov identifier: NCT05050084. Updated June 25, 2026. Accessed April 7, 2026. https:\/\/clinicaltrials.gov\/study\/NCT05050084"},{"key":"zoi260903r13","unstructured":"Testing the addition of the drug apalutamide to the usual hormone therapy and radiation therapy after surgery for prostate cancer, INNOVATE Trial. ClinicalTrials.gov identifier: NCT04134260. Updated June 25, 2026. Accessed April 7, 2026. https:\/\/clinicaltrials.gov\/study\/NCT04134260"},{"key":"zoi260903r14","unstructured":"Using appropriate price indices for analyses of health care expenditures or income across multiple years. Medical Expenditure Panel Survey. Agency for Healthcare Research and Quality. Accessed July 30, 2026. https:\/\/meps.ahrq.gov\/about_meps\/Price_Index.shtml"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2853882\/shen_2026_oi_260903_1788358378.26627.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T15:00:37Z","timestamp":1789052437000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2853882"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,10]]},"references-count":22,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2026.33031","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,10]]}}}